Compare Chewy Inc (CHWY) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chewy Inc vs Eli Lilly And Co — how do they compare? Chewy Inc trades at $22.36 (market cap $9.20B), while Eli Lilly And Co trades at $1,219.87 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 117.4× Chewy Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| CHWY | LLY | |
|---|---|---|
Market Cap | $9.20B | $1.08T |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $1.24K |
52-Week Low | $17.51 | $639.43 |
Enterprise Value | $9.16B | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chewy (CHWY) trades at $22.16, down 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though the net margin remains thin at 1.99%. Recent news highlights insider sales and institutional position changes, while analyst consensus remains strongly bullish with an 81.58% buy rating and a $33.82 price target.
The outlook is mixed: strong revenue growth and high ROE support upside potential, but thin margins, competitive pressures, and recent insider selling pose risks. Earnings beats in recent quarters provide momentum, yet the stock faces volatility near key support at $22. Investors should weigh robust analyst optimism against execution challenges in the pet care market.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
